Total and free propranolol levels in sensitive and resistant patients
- 1 February 1983
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 33 (2) , 163-171
- https://doi.org/10.1038/clpt.1983.25
Abstract
The clinical effects of the .beta.-adrenergic inhibitor propranolol are believed to correlate best with circulating levels of free drug, the component of total drug concentration that is not bound to plasma proteins and is therefore free to interact with tissue .beta.-receptors. The radioreceptor assay for propranolol was used to determine total and free propranolol levels in 32 hospitalized patients [with a variety of conditions, including hypertension and angina pectoris] receiving a wide range of doses (40-1280 mg/day). Free propranolol was determined by equilibrium dialysis and by the erythrocyte drug level. Erythrocyte levels correlated strongly with free drug, as determined by equilibrium dialysis. Mean percent free propranolol was 16.9 .+-. 2.4 ng/ml (SEM [standard error of the mean]) by equilibrium dialysis and 18.8 .+-. 2.3 ng/ml (SEM) by the red cell level. Despite considerable variability in the actual level achieved at any given dose, total and free propranolol concentrations were related to dose. A weaker correlation for free drug concentration resulted from variability in free drug among responsive patients (mean .+-. SD free propranolol was 13.5 .+-. 8.8 ng/ml), and suggested a threshold level of free drug required to achieve clinical effects. Six patients were resistant to high doses of propranolol. Excessive protein binding was noted in 4, suggesting abnormalities at the level of protein-drug interaction. Several other possible mechanisms for propranolol resistance became apparent.This publication has 22 references indexed in Scilit:
- Comparison of the Immediate Effects of Five β-Adrenoreceptor-Blocking Drugs with Different Ancillary Properties in Angina PectorisNew England Journal of Medicine, 1979
- Influence of pentobarbital on effect and plasma levels of alprenolol and 4‐hydroxy‐alprenololClinical Pharmacology & Therapeutics, 1979
- Increased Plasma Protein Binding of Propranolol and Chlorpromazine Mediated by Disease-Induced Elevations of Plasma α1Acid GlycoproteinNew England Journal of Medicine, 1978
- Beta-adrenergic blockade in acute myocardial infarctionLife Sciences, 1978
- Biological determinants of propranolol disposition in manClinical Pharmacology & Therapeutics, 1978
- The Influence of Cirrhosis on Steady-State Blood Concentrations of Unbound Propranolol after Oral Administration1Clinical Pharmacokinetics, 1978
- Pathophysiologic and pharmacokinetic determinants of the antihypertensive response to propranololClinical Pharmacology & Therapeutics, 1977
- PLASMA-PROTEIN BINDING OF BASIC DRUGS .1. SELECTIVE DISPLACEMENT FROM ALPHA1-ACID GLYCOPROTEIN BY TRIS(2-BUTOXYETHYL) PHOSPHATE1977
- Plasma binding and the affinity of propranolol for a beta receptor in manClinical Pharmacology & Therapeutics, 1976
- Propranolol in the Treatment of HypertensionNew England Journal of Medicine, 1976